Phase II clinical trial of orelabrutinib for the treatment of immune thrombocytopenia purpura
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Thrombocytopenic purpura
- Focus Therapeutic Use
Most Recent Events
- 21 Aug 2022 According to a InnoCare Pharma media release, this trial will complete patient enrollment soon.
- 22 Mar 2022 According to a InnoCare Pharma media release, first patient was dosed in China in February 2022.
- 03 Sep 2021 New trial record